DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Eritoran is an investigational drug.
There have been 4 clinical trials for Eritoran. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2006.
The most common disease conditions in clinical trials are Insulin Resistance, Hypersensitivity, and Toxemia. The leading clinical trial sponsors are Eisai Inc., The University of Texas Health Science Center at San Antonio, and Nicolas Musi.
Recent Clinical Trials for Eritoran
|The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects||Nicolas Musi||Phase 2|
|The Role of TLR4 on Lipid-induced Insulin Resistance||The University of Texas Health Science Center at San Antonio||Phase 2|
|A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors||Eisai Inc.||Phase 1|